China Pharma Holdings, Inc. (CPHI) |
| 0.63 -0.02 (-3.05%) 04-14 14:31 |
| Open: | 0.5927 |
| High: | 0.64 |
| Low: | 0.59 |
| Volume: | 18,674 |
| Market Cap: | 2(M) |
| PE Ratio: | -0.09 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.79 |
| Resistance 1: | 0.68 |
| Pivot price: | 0.63 |
| Support 1: | 0.59 |
| Support 2: | 0.53 |
| 52w High: | 2.6 |
| 52w Low: | 0.5 |
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Thu, 02 Apr 2026
China Pharma Delays 10-K but Shows Narrowing Losses - The Globe and Mail
Wed, 01 Apr 2026
China Pharma Holdings 10-K: Revenue $4.14M, Loss per Share $(0.74) - TradingView — Track All Markets
Wed, 01 Apr 2026
China Pharma (NYSE American: CPHI) details 2025 losses and China policy risks - Stock Titan
Sun, 22 Mar 2026
If You Invested $1,000 in China Pharma (CPHI) - Stock Titan
Tue, 25 Nov 2025
Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Tue, 03 Jun 2025
CPHI Forecast — Price Prediction for 2026. Should I Buy CPHI? - Intellectia AI
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |